News

News

No. Title Written by Date Read
17 A successful presentation of a First-in-Class drug targeting ‘BTN1A1’ at the AACR 2021 Admin 21.04.16 104
16 Research on STCube’s Small Molecule Immunotherapeutic Agent for Pancreatic Cancer Published in Prestigious Scientific Journal Admin 20.12.09 234
15 STCube, Inc. Obtains U.S. Patent for Proprietary Anti-PD-1 Antibody Admin 20.10.30 214
14 Enter into CDMO Agreement with Samsung Biologics /Eyes of CEO/Hankyung TV Admin 20.08.13 640
13 STCube signs additional development and manufacturing agreement with Samsung Biologics Admin 20.07.12 286
12 STCube Presents Data on Its Proprietary PD-1 Antibody at AACR Admin 20.06.23 368
11 STCube Applies for a U.S. Patent on the COVID-19 Anti-viral Treatment Using 'STT-003' Admin 20.03.30 279
10 STCube Initiates a CRO Contract for Development of COVID-19 Treatment Using ‘STT-003’ Admin 20.03.23 282
9 STCube Publishes Research Paper on Its Antibody to Immune-checkpoint Inhibitor PD-1 in Cancer Research, an International Academic Journal Admin 20.03.12 288
8 STCube and Samsung Biologics Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug Admin 20.03.03 313